Drugs / Mesoglycan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03428711 | Mar 2018 → Dec 2024 | thrombophlebitis | Quovadis Associazione | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02254850 | May → Aug 2013 | metabolic syndrome X | Federico II University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06101992 Comparator | Jan → Mar 2024 | hemorrhoid | Societa Italiana di Chirurgia ColoRettale | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mesoglycan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02254850 ↗ |
| Modality | Other / unclassified | “is a complex mucopolysaccharide” NCT03428711 ↗ |
| Route | Intramuscular | “intramuscular administration” NCT02254850 ↗ |